

Manuscript Number: ARCHIVES-PMR-D-10-00494R1

Title: Kinematic features of rear-foot motion using anterior and posterior AFOs in stroke patients with hemiplegic gait

Article Type: Original Article

Keywords: Orthotic Devices; Stroke; Biomechanics; Gait

Corresponding Author: Dr. Simon F.T. Tang,

Corresponding Author's Institution:

First Author: Chih-Chi Chen

Order of Authors: Chih-Chi Chen; Wei-Hsien Hong; Chin-Man Wang; Chih-Kuang Chen; Katie Pei-Hsuan Wu; Chao-Fu Kang; Simon F.T. Tang

Abstract: Title: Kinematic features of rear-foot motion using anterior and posterior AFOs in stroke patients with hemiplegic gait

Running head: A-AFO and P-AFO use in hemiplegic gait

Key Words: Orthotic devices, Stroke, Biomechanics, Gait.

Objective: To evaluate the kinematic features of rear-foot motion during gait in hemiplegic stroke patients, using anterior ankle foot orthoses (A-AFOs), posterior AFOs (P-AFOs), and no orthotic assistance.

Design: Crossover design with randomization for the interventions.

Setting: A rehabilitation centre for adults with neurological disorders.

Participants: Fourteen patients with hemiplegia due to stroke and eleven able-bodied subjects.

Interventions: Subjects with hemiplegia were measured walking under 3 conditions with randomized sequences: (1) with an A-AFO, (2) with a P-AFO, and (3) without an AFO. Control subjects were measured walking without AFO to provide a normative reference.

Main Outcome Measures: Rear-foot kinematic change in the sagittal, coronal, and transverse planes.

Results: In the sagittal plane, as compared to walking with an A-AFO or without an AFO, the P-AFO significantly decreased plantarflexion to neutral at initial heel contact ($P = 0.001$) and the swing phase ($P < 0.001$), and increased dorsiflexion at the stance phase ($P = 0.002$). In the coronal plane, the A-AFO significantly increased maximal eversion to neutral (less inversion) at the stance phase ($P = 0.025$), and decreased the maximal inversion angle at the swing phase when compared with using no AFO ($P = 0.005$). The P-AFO also decreased the maximal inversion angle at the swing phase as compared to no

AFO ($P = 0.005$). In the transverse plane, when compared with walking without an AFO, the A-AFO and P-AFO decreased the adduction angle significantly at initial heel contact ($P = 0.004$).

Conclusions: For post-stroke hemiplegic gait, the P-AFO was better than the A-AFO in enhancing rear-foot dorsiflexion during the whole gait cycle. The A-AFO was superior to the P-AFO in correcting excessive rear-foot inversion at the stance phase. Both the A-AFOs and P-AFOs helped correct an inverted foot at the swing phase.

Key words: Orthotic Devices, Stroke, Biomechanics, Gait.

Dear Dr. Rodgers,


Thank you for your email telling me that the Editorial Board sees merit in my manuscript. Also I would like to thank Archives of PMR for finding two such outstanding and reasonable reviewers for me. Comments from the two reviewers were indeed very helpful. Revising the manuscript according to the comments from reviewers certainly made the manuscript more presentable.

We revised the manuscript as suggestion and focused on the areas as you pointed out, 1. Clarify comparison of kinematic variables between conditions, 2. Provide additional information about subjects and 3. Provide more description of the A-AFO.

The manuscript has been read by a native English speaker and edited for grammar errors. I hope you and the reviewers will like the revisions I have done. It will certainly be my greatest honor if this manuscript can be published in the renowned Archives of PMR.

Enclosed below you will find our replies to both reviews. We also made detailed comparison lists before and after revision for reviewers to easily review. Please allow us let one of our members as co-authors (Chao-Fu Kang, MD) because he helped a lot in revised this manuscript.

Thank you again. Please feel free to contact me at anytime if I can be of any further assistance. Take care!



Simon FT Tang

Professor and Program Director

Department of Physical Medicine and Rehabilitation,

Chang Gung Memorial Hospital

5, Fu-Hsin ST., Kwei-Shan, Tao-Yuan County, 333, Taiwan

Replies to Reviewer 1

→As suggested by reviewer 1, we have checked all manuscript, clarified the comparisons and modulate those confusing statements.

→Methods: We have added a more detailed description about the A-AFO. We have also corrected the typing errors about the P-AFO. We also added a description to explain why we let subjects walking barefoot with AFO.

→Results: A table is now constructed as suggested. The table clearly provides information on the sex, age, time since stroke, involved side, Brunnstrom stage, muscle tone, use of assistive device, and prior AFO use.

→A detailed comparison list before and after revision for reviewer 1 is listed in the following page.

Comparison List for Reviewer 1

Suggestion 1:

The comparison of kinematic variables between conditions often is not clear. Often times, the variable is described as "increased" or decreased", but it is not clear what the value is being compared to. Examples are: page 7, line114-115; 116-117; 119; p8 129-130, and abstract. These are specific examples but the authors should check and clarify all comparisons.

Reply: We have checked all manuscript and clarify the comparison as following:

Before Revision	After revision
<p>Abstract</p> <p>Results</p> <p>At initial heel contact, the rear-foot showed increased dorsiflexion while wearing P-AFOs ($P=0.001$). During the stance phase, wearing the P-AFO increased the dorsiflexion angle more significantly than wearing the A-AFO or nothing ($P=0.002$). The A-AFO lessened inversion and increased the maximal eversion angle ($P=0.025$). During the swing phase, decreased maximal plantarflexion and an increased dorsiflexion angle were noted only wearing the P-AFO ($P<0.001$). With both the A-AFO and P-AFO, the inversion angle was significantly decreased as compared to wearing nothing ($P=0.005$).</p> <p>Conclusions</p> <p>A-AFOs were superior in correcting excessive rear-foot inversion, while P-AFOs had the advantage in enhancing rear-foot dorsiflexion. P-AFOs also helped correct an inverted foot at the swing phase.</p>	<p>Abstract</p> <p>Results</p> <p><u>In the sagittal plane, as compared to walking with an A-AFO or without an AFO, the P-AFO significantly decreased plantarflexion to neutral at initial heel contact ($P = 0.001$) and the swing phase ($P < 0.001$), and increased dorsiflexion at the stance phase ($P = 0.002$). In the coronal plane, the A-AFO significantly increased maximal eversion to neutral (less inversion) at the stance phase ($P = 0.025$), and decreased the maximal inversion angle at the swing phase when compared with using no AFO ($P = 0.005$). The P-AFO also decreased the maximal inversion angle at the swing phase as compared to no AFO ($P = 0.005$). In the transverse plane, when compared with walking without an AFO, the A-AFO and P-AFO decreased the adduction angle significantly at initial heel contact ($P = 0.004$).</u></p>

Before Revision	After revision
<p>Abstract-Conclusions</p> <p>A-AFOs were superior in correcting excessive rear-foot inversion, while P-AFOs had the advantage in enhancing rear-foot dorsiflexion. P-AFOs also helped correct an inverted foot at the swing phase.</p>	<p>Abstract-Conclusions</p> <p><u>For post-stroke hemiplegic gait, the P-AFO was better than the A-AFO in enhancing rear-foot dorsiflexion during the whole gait cycle. The A-AFO was superior to the P-AFO in correcting excessive rear-foot inversion at the stance phase. Both the A-AFOs and P-AFOs helped correct an inverted foot at the swing phase.</u></p>

Before Revision	After revision
<p>Results (Page 7, line 114-119)</p> <p>At initial heel contact, the rear-foot showed increased dorsiflexion while wearing P-AFOs. The subjects showed a trend in decreasing the inversion rear-foot angle after wearing A-AFOs, but it was not significant ($P=0.064$). Wearing the A-AFO and the P-AFO decreased the adduction angle significantly. During the stance phase, wearing the P-AFO increased the dorsiflexion angle more significantly than wearing the A-AFO or nothing. The A-AFO lessened inversion and increased the maximal eversion angle. There was no significant difference in the maximal abduction angle in any of the AFO trials. During the swing phase, decreased maximal plantarflexion and an increased dorsiflexion angle were noted only wearing the P-AFO. With both the A-AFO and P-AFO, the inversion angle was significantly decreased as compared to wearing nothing. No significant difference could be seen in the abduction and adduction angles with or without the A-AFO or P-AFO.</p>	<p>Results (page 8, line 136-146)</p> <p><u>In the sagittal plane, as compared to walking with an A-AFO or without an AFO, the P-AFO significantly decreased plantarflexion to neutral at initial heel contact and the swing phase and increased dorsiflexion at the stance phase. In the coronal plane, the A-AFO significantly increased maximal eversion to neutral (less inversion) at the stance phase and decreased the maximal inversion angle at the swing phase when compared with not using an AFO. The P-AFO also decreased the maximal inversion angle at the swing phase when compared with not using an AFO. In the transverse plane, as compared to walking without an AFO, the A-AFO and P-AFO conditions decreased the adduction angle significantly at initial heel contact. There were no significant differences in maximal adduction and the maximal abduction angles among the three AFO conditions during the stance and swing phases respectively.</u></p>

Before Revision	After revision
<p>Discussion (p8 125-131)</p> <p>Our aim in this study was to assess the kinematic characteristics of rear-foot joint change during gait in hemiplegic stroke patients using A-AFOs, P-AFOs, and no orthotic assistance. Previously, the choice of anterior or posterior AFO was often based on the practitioner’s experience and the patients’ preference. In both the stance and the swing phases, our results showed that A-AFOs were superior in correcting excessive rear-foot inversion, while P-AFOs had the advantage in enhancing rear-foot dorsiflexion. P-AFOs also helped correct an inverted foot at the swing phase.</p>	<p>Discussion (p9 148-158)</p> <p><u>The incidence of equinovarus foot in stabilized vascular hemiplegia was reported to be about 18%.¹⁷ The equinovarus foot shifts weight bearing from the heel to the lateral plantar surface, which can cause loss of balance and reduce walking safety. This condition also has a strong correlation to the presence of claw toes.^{18, 19} An AFO has often been prescribed to facilitate ankle control for the equinus and/or varus foot. This study investigated the kinematic change in rear-foot joint control during gait in hemiplegic stroke patients using A-AFOs, P-AFOs, and no AFO assistance. As compared to using no AFO, the A-AFO decreased rear-foot inversion at the stance and swing phases. The P-AFO increased rear-foot dorsiflexion during the whole gait cycle in comparison with the A-AFO and P-AFO. The P-AFO also decreased rear-foot inversion at the swing phase as compared to using no AFO.</u></p>

Suggestion 2:

In addition, in some locations, the comparison of the A-AFO to other conditions seems misleading. For example, the paper reads, 'our results showed that the A-AFOs were superior in correcting excessive rear foot inversion.' (129-130; 171), but elsewhere (lines 134-136) the text indicates there were no differences in gait parameters between the brace conditions after statistical analysis.

Reply: We have clarified the comparison and modulate these confusing statements.

Before revision	After revision
<p>Discussion (line 134-136)</p> <p>After wearing either A-AFOs or P-AFOs, we noted no significant difference in the gait parameters after statistical analysis.</p>	<p>Discussion (p10 line 161-162)</p> <p><u>After wearing either A-AFOs or P-AFOs, we noted no significant difference in walking speed, step length and cycle time after statistical analysis.</u></p>

Suggestion 3.

The paper correctly states in several locations that brace selection will be dependent upon the patient's motor control and gait patterns (i.e., line 198). However, the study does not adequately describe the clinical characteristics of the people with a history of stroke to allow interpretation of the results. The authors should provide additional information about subjects; for example, severity of deficits (some type of standardized measure), tone, use of assistive device, and prior AFO use.

Reply:

We have added a table 1 to provide more detailed information about the subjects.

Table 1: Information about stroke subjects with hemiplegia

Subject Number	Sex	Age(y)	Years and months since stroke	Involved Side R/L	Brunnstrom stage of involved lower limb	Ankle MAS	Use of assistive device	Prior AFO use
1	M	47	5y6m	L	V	3	N	Y(A-AFO)
2	M	51	3y8m	L	IV	3	N	Y(A-AFO)
3	M	47	3y9m	R	V	1+	N	N
4	M	67	2y5m	L	IV	1+	N	N
5	M	60	7m	R	III-IV	3	N	Y(A-AFO)
6	M	53	5y4m	R	V	2	N	N
7	M	53	8m	L	III	2	N	N
8	M	51	3y4m	R	III	3	N	Y(A-AFO)
9	M	43	10m	L	V	2	N	Y(A-AFO)
10	M	70	5m	R	V	1+	N	N
11	W	49	2m	R	IV	2	N	Y(A-AFO)
12	W	56	2y2m	R	IV	2	N	Y(A-AFO)
13	W	72	1y	R	V	2	N	N
14	W	71	4y4m	L	IV	1+	N	Y(A-AFO)

MAS: Modified Ashworth Scale. N: no, Y: yes.

Suggestion 4, The A-AFO will not be familiar to many readers, and although it has been described elsewhere in the literature, it should be described in greater detail here; ie, specific anatomical boundaries of trim line, rationale for design.

Reply: We have added a more detailed description about the A-AFO.

Before revision	After revision
<p>Method Nil (not mentioned before revision)</p>	<p>Method (p4 48-58) <u>The A-AFO was made of a low temperature 3.2 mm thick thermoplastic material, Orfit.^a A piece of thermoplastic was cut in the shape of a bottle cap opener (fig 1). The pretibial and ankle parts were padded with closed-cell foam, Kushionflex padding.^b Subjects were asked to sit with their knee in a 90 degree flexion and their ankle in a neutral position. After softening the thermoplastic in a hot water tank (60°C), the anterior AFO was molded directly to the subject's lower limb, with her or his foot going through the hole in the bottle cap opener section. The sole part was 6 cm in width, with its anterior trim line just behind the metatarsal heads. The foot and ankle portions were folded to form the medial and lateral bars. The upper part was molded onto the ankle and lower half of the tibia without covering the medial and lateral malleoli. Velcro straps^c were placed at the ankle level and upper part of the orthosis (see fig 2). Usually, we can make an A-AFO within half an hour.</u></p>

Suggestion 5, The paper states that P-AFO trim lines were anterior to both malleoli (line 55), but such a trim line seems quite restrictive and different from Fig 1. Please clarify.

Reply: We have corrected the typing errors and added more description about the P-AFO.

Before revision	After revision
<p>Method (p4 52-55)</p> <p>The AFO extended distally under the toes and covered the mediolateral border of the foot. Proximally, it covered the posterior portion of the leg to 5 cm below the fibular head. The trim lines were anterior to both malleoli. Three straps crossed the anterior upper tibia, front of the ankle, and the mid-foot area (See fig 1).</p>	<p>Method (p4 59-67)</p> <p><u>We used leaf-spring AFO in comparison with A-AFO not only because it is commonly used in clinical situations but it dose not cover malleoli, which is similar to the A-AFO. Each P-AFO was fabricated using polypropylene with the ankle in a neutral position. The footplate was cut to the metatarsal head. Proximally, it covered the posterior portion of the leg to 5 cm below the fibular head. The medial and lateral trim lines over the ankle were posterior to both malleoli. Three straps crossed the proximal end of shank, the front of the ankle, and the mid-foot area (see fig 2). We used three straps to hold the P-AFO instead of standard single strap at the upper shank because we let subjects walk barefoot with P-AFO without shoes assistance.</u></p>

Suggestion 6, Why did subjects walk barefoot with P-AFO? In America, walking barefoot with a P-AFO would be very unusual.

Reply: We added a description to explain why we let subjects walking barefoot with P-AFO.

Before revision	After revision
Nil (not mentioned before revision)	Method. (P5 68-70) <u>The decision to analyze subjects walking barefoot with AFOs was based upon: (1) our need to know the real function of the AFO without the assistance of a shoe; and, (2) our interest in conforming to the custom in Asia countries of walking barefoot indoors.</u>

Replies to Reviewer 2

➔Introduction: As suggested by reviewer 2, we have added the suggested references to expose the interest of AFOS.

➔Methods: We made a hole at P-AFO to allow calcaneal marker directly placed on the skin.

Thank you for reminding us to add the important description. We also added pictures to clarify the marker position.

➔Results: We have corrected the typing error in table 3.

➔Discussions: Thank you for your kindly suggestion. We have added the references and a discussion of risk of walking with equinovarus foot as your suggestion.

➔A detailed comparison list before and after revision for reviewer 2 is listed in the following page.

Comparison List for Reviewer 2

Reviewer 2

Suggestion 1.

Introduction:

Previous pertinent literature: page2, line15 to 24: The following article is missing in the references to expose the interest of AFOS: Ann Readapt Med Phys. 2008 Apr;51(3):147-53. Epub 2008 Jan 7.[Assessment of the Chignon dynamic ankle-foot orthosis using instrumented gait analysis in hemiparetic adults]. Bleyenheuft C, Caty G, Lejeune T, Detrembleur C.

Reply: We have added the suggested references to expose the interest of AFOS.

Before revision	After revision
<p>Introduction (P2 19-22)</p> <p>Several studies evaluated the effects of posterior AFOs (P-AFOs) on stroke patients and demonstrated improvement in gait parameters including stride length, gait velocity and cadence,⁴⁻⁶ gait stability,⁴ balance control,⁷ energy cost of walking,⁸ and functional status.⁵</p>	<p>Introduction (P2 19-22)</p> <p>Several studies evaluated the effects of P-AFOs on stroke patients and demonstrated improvement in gait parameters including stride length, gait velocity and cadence,⁴⁻⁶ gait stability,⁴ balance control,⁷ <u>energy cost of walking</u>,^{8,9} and functional status.⁵</p> <p>Reference</p> <p>9.Bleyenheuft C, Caty G, Lejeune T, Detrembleur C. Assessment of the Chignon dynamic ankle-foot orthosis using instrumented gait analysis in hemiparetic adults. Ann Readapt Med Phys 2008;51(3):154-60.</p>

Suggestion 2.

Methods : p5 line 63-65. it seems the posterior marker is placed on the p-AFO. In this condition, are the authors sure that the kinematic data show the mobility of the foot rather the mobility of the P-AFO. Please discuss this point.

Reply:

We made a hole at P-AFO to allow calcaneal marker directly placed on the skin. We have added the picture and statement in the methods.

Before revision	After revision
<p>Method –Equipment (p5 62-64)</p> <p>A marker was placed on the midline of the calcaneal posterior process, and, with the subject standing, individual markers were also placed on the medial and lateral sides of the calcaneus in a plane parallel to the ground (fig 2).</p>	<p>Method –Equipment (p5 80-81)</p> <p><u>We made one hole in each P-AFO to allow placement of the calcaneal markers directly onto the skin</u> (fig 2).</p>

Suggestion 3.

P7 line 111 : the authors wrote that the stroke patients showed less maximal plantarflexion than the healthy control group, but the table 3 does not show that. Is there an error in the table 3?

Reply. We have corrected table 3 as following.

Table 3. Rear-foot kinematics during gait for the involved limb of stroke subjects and control subjects walking barefoot with their self-selected comfortable walking speed

Gait phase	Initial heel contact	Stance phase	Swing phase
Sagittal plane	Plantarflexion	Maximal Dorsiflexion	Maximal Plantarflexion
Angle			
Control	6.3±4.7	-8.6±2.9	8.4±3.6
Stroke	8.5±5.7	-2.4±6.4	<u>5.4±4.0</u>
<i>P</i> -value	0.307	0.018*	0.048*
Coronal plane	Inversion	Maximal Eversion	Maximal Inversion
Angle			
Control	-1.4±2.8	-4.6±3.0	7.7±2.6
Stroke	8.2±4.5	4.4±5.0	10.5±4.7
<i>P</i> -value	<0.001**	<0.001**	0.177
Transverse plane	Adduction	Maximal Adduction	Maximal Abduction
Angle			
Control	1.2±3.6	11.3±4.5	7.7±2.6
Stroke	8.9±4.3	11.5±5.5	3.7±5.4
<i>P</i> -value	<0.001**	0.850	0.118

*: *P* <0.05; **: *P* <0.01; plantarflexion (+), dorsiflexion (-); inversion (+), eversion (-); adduction (+), abduction (-).

Suggestion 4. Discussion: P8 line126-132 : Since the main result is the importance of the varus-foot stabilization with A-AFO it could be interesting to discuss the incidence of varus equinus and value its consequences on gait (see references below): Claw toes in hemiplegic patients after stroke.Laurent G, Valentini F, Loiseau K, Hennebelle D, Robain G. Ann Phys Rehabil Med. 2010 Mar;53(2):77-85. Epub 2010 Jan 13. English, French. PMID: 20097630 [PubMed - indexed for MEDLINE]

Epidemiology of pes varus and/or equinus one year after a first cerebral hemisphere stroke: apropos of a cohort of 86 patients] Verdié C, Daviet JC, Borie MJ, Popielarz S, Munoz M, Salle JY, Rebeyrotte I, Dudognon P. Ann Readapt Med Phys. 2004 Mar;47(2):81-6.

Reply: We have added the references and a discussion of risk of walking with equinovarus foot.

Before revision	After revision
<p>Discussion (p8 126-132) Nil (not mentioned before revision)</p>	<p>Discussion (p9 148-151) <u>The incidence of equinovarus foot in stabilized vascular hemiplegia was reported to be about 18%.¹⁷ The equinovarus foot shifts weight bearing from the heel to the lateral plantar surface, which can cause loss of balance and reduce walking safety. This condition also has a strong correlation to the presence of claw toes.^{18, 19}</u></p> <p>Reference 17. Verdie C, Daviet JC, Borie MJ, Popielarz S, Munoz M, Salle JY et al. [Epidemiology of pes varus and/or equinus one year after a first cerebral hemisphere stroke: apropos of a cohort of 86 patients]. Ann Readapt Med Phys 2004;47(2):81-6. 19. Laurent G, Valentini F, Loiseau K, Hennebelle D, Robain G. Claw toes in hemiplegic patients after stroke. Ann Phys Rehabil Med 2010;53(2):77-85.</p>

Suggestion 5. Moreover, since the A-AFO is superior in correcting excessive rear-foot inversion, a discussion of risk of walking with a varus-equinus foot could be interesting.

Reply:

Besides the discussion of altered rear-foot kinematics in hemiplegic gait and its consequences in altered gait pattern (p11 181-184). We have added a discussion of risk of walking with equinovarus foot as your suggestion.

Before revision	After revision
Nil (not mentioned before revision)	Discussion (p9 149-151) <u>The equinovarus foot shifts weight bearing from the heel to the lateral plantar surface, which can cause loss of balance and reduce walking safety. This condition also has a strong correlation to the presence of claw toes.</u> ^{18, 19}

1 Word counts for the main text: 2969, Word counts for Abstract: 333.

2 **Title: Kinematic features of rear-foot motion using anterior and posterior AFOs in**
3 **stroke patients with hemiplegic gait**

4 **Names and affiliations of the authors:** Chih-Chi Chen, MD¹, Wei-Hsien Hong, PHD²,
5 Chin-Man Wang MD¹, Chih-Kuang Chen, MD¹, Katie Pei-Hsuan Wu, MD¹, Chao-Fu Kang,
6 MD¹ & Simon F.T. Tang, MD¹

7 **From** the ¹. Department of Physical Medicine and Rehabilitation, Chang Gung Memorial
8 Hospital and Chang Gung University, Linkou and ². School of Sports Medicine, China
9 Medical University, Taichung, Taiwan

10 **Running head: A-AFO and P-AFO use in hemiplegic gait**

11 **Grant & Financial Support:** National Science Council, Republic of China (Grant No. NSC
12 98-2119-M-009-019).

13 **Financial Disclosure:** We certify that no party having a direct interest in the results of the
14 research supporting this article has or will confer a benefit on us or on any organization with
15 which we are associated AND, if applicable, we certify that all financial and material
16 support for this research (eg, NIH or NHS grants) and work are clearly identified in the title
17 page of the manuscript.

18 **Corresponding author:**

19 Professor Simon F.T. Tang, MD

20 Department of Physical Medicine & Rehabilitation
21 Chang Gung Memorial Hospital & Chang Gung University Taoyuan, Taiwan
22 5, Fu-Hsin St, Kwei-Shan, Tao-Yuan, 333, Taiwan
23 Tel: +886-3-328-1200 ext. 3846
24 Fax:+886-3-327-4850
25 E-mail: fttang@adm.cgmh.org.tw
26 bluegirl5477@yahoo.com.tw

1 **Title: Kinematic features of rear-foot motion using anterior and posterior AFOs in**

2 **stroke patients with hemiplegic gait**

3 **Running head: A-AFO and P-AFO use in hemiplegic gait**

4 **Key words:** Orthotic Devices, Stroke, Biomechanics, Gait.

5

6 **Introduction**

7 Stroke patients often have upper motor neuron syndrome with a resultant loss of strength
8 and dexterity, impaired motor control, increased spasticity, hyperreflexia, co-contraction,
9 and spastic dystonia in the affected limbs. These conditions result in inappropriate and
10 involuntary posturing and contribute to abnormal gait pattern and impaired walking ability.¹
11 Clinically, we can identify more than one type of gait pattern across stroke patients, such as
12 the equinus and equinovarus gaits, indicating that people who have suffered strokes need to
13 use different strategies to achieve the goal of walking.²

14 AFOs are often prescribed to stroke patients and are designed to provide mediolateral
15 ankle stability during stance and adequate toe clearance during swing and to promote heel
16 strike.³ Conventional plastic AFOs have a posterior leaf-type design, and are fabricated by a
17 lamination or vacuum-forming technique over a positive plaster model of the limb.⁴
18 A-AFOs are low-temperature ankle foot orthoses commonly used in Asian countries for
19 convenience when walking indoors. Several studies evaluated the effects of P-AFOs on
20 stroke patients and demonstrated improvement in gait parameters including stride length,
21 gait velocity and cadence,⁴⁻⁶ gait stability,⁴ balance control,⁷ energy cost of walking,^{8,9} and
22 functional status.⁵ Some studies evaluated the A-AFO function and suggested that A-AFOs
23 also work effectively for gait parameters,¹⁰ walking ability,¹¹ and balance control¹² in
24 hemiplegic stroke patients.

25 Since ankle motor control in stroke patients is variable, and the designs of A-AFOs and
26 P-AFOs are different, we speculated that different post-stroke gait patterns could benefit
27 from different AFO types. We analyzed the shank-calcaneus rotation angle, as
28 representative of rear-foot movement, by means of a 3-dimensional motion analysis
29 system.¹³ To our knowledge, this is the first study to compare the kinematic changes in
30 rear-foot movement during gait in hemiplegic stroke patients using either A-AFOs or
31 P-AFOs.

32 **Methods**

33 **Subjects**

34 For this study, we recruited 14 stroke subjects with hemiplegia. The inclusion criteria for
35 the study group were as follows: (1) diagnosis of unilateral hemiplegia caused by either
36 hemorrhagic or ischemic stroke; (2) ability to follow simple verbal commands or
37 instructions; and, (3) ability to ambulate independently. Subjects were excluded if they had
38 any of the following conditions: (1) medical problems other than stroke that would interfere
39 with their gait; or, (2) foot-related premorbid or comorbid orthopedic problems. All patients
40 underwent neuroimaging studies, including computed tomography or magnetic resonance
41 imaging of the brain to confirm the diagnosis of stroke at an early stage. We also recruited
42 11 normal subjects, who had no known neurological and orthopedic impairments, to serve
43 as our control group. This study was approved by the local medical ethics and the human

44 clinical trial committees (Chang Gung Memorial Hospital, Taiwan), and all participants
45 signed the informed consent.

46 **AFO design**

47 A-AFOs and P-AFOs for the study were custom-made for each subject by a certified
48 orthotist. Fabrication of an anterior AFO was well documented in our previous study.¹¹ The
49 A-AFO was made of a low temperature 3.2 mm thick thermoplastic material, Orfit.^a A
50 piece of thermoplastic was cut in the shape of a bottle cap opener (fig 1). The pretibial and
51 ankle parts were padded with closed-cell foam, Kushionflex padding.^b Subjects were asked
52 to sit with their knee in a 90 degree flexion and their ankle in a neutral position. After
53 softening the thermoplastic in a hot water tank (60°C), the anterior AFO was molded
54 directly to the subject's lower limb, with her or his foot going through the hole in the bottle
55 cap opener section. The sole part was 6 cm in width, with its anterior trim line just behind
56 the metatarsal heads. The foot and ankle portions were folded to form the medial and lateral
57 bars. The upper part was molded onto the ankle and lower half of the tibia without covering
58 the medial and lateral malleoli. Velcro straps^c were placed at the ankle level and upper part
59 of the orthosis (see fig 2). Usually, we can make an A-AFO within half an hour.

60 The P-AFO used in this study was the plastic leaf-spring AFO¹⁴. We used leaf-spring
61 AFO in comparison with A-AFO not only because it is commonly used in clinical situations
62 but it dose not cover malleoli, which is similar to the A-AFO. Each P-AFO was fabricated

63 using polypropylene with the ankle in a neutral position. The footplate was cut to the
64 metatarsal head. Proximally, it covered the posterior portion of the leg to 5 cm below the
65 fibular head. The medial and lateral trim lines over the ankle were posterior to both malleoli.
66 Three straps crossed the proximal end of shank, the front of the ankle, and the mid-foot area
67 (see fig 2). We used three straps to hold the P-AFO instead of standard single strap at the
68 upper shank because we let subjects walk barefoot with P-AFO without shoes assistance.
69 The decision to analyze subjects walking barefoot with AFOs was based upon: (1) our need
70 to know the real function of the AFO without the assistance of a shoe; and, (2) our interest
71 in conforming to the custom in Asia countries of walking barefoot indoors.

72 **Equipment**

73 A Vicon motion analysis system^c was used to collect the kinematic data. The Vicon MS
74 system included 8 infrared cameras for acquiring, at a rate of 100Hz, the kinematic
75 trajectories of the reflective markers attached to the subject's lower limbs. We placed 7
76 spherical retro-reflective markers (diameter 1.4 cm) directly on the subject's affected-side
77 calcaneus and shank. Two markers were placed on the medial and lateral tibial condyles,
78 and 2 markers were also placed on the medial and lateral malleoli. A marker was placed on
79 the midline of the calcaneal posterior process, and, with the subject standing, individual
80 markers were also placed on the medial and lateral sides of the calcaneus in a plane parallel
81 to the ground. We made one hole in each P-AFO to allow placement of the calcaneal

82 markers directly onto the skin (fig 2). Three-dimensional marker trajectories were used to
83 determine the rear-foot motion angles in the sagittal (dorsiflexion–plantarflexion), coronal
84 (inversion–eversion), and transverse (abduction–adduction) planes.

85 **Data collection**

86 We evaluated and recorded stroke participants’ motor recovery and ankle muscle tone
87 using a Brunnstrom stage¹⁵ and modified Ashworth Scale (MAS),¹⁶ respectively. All
88 subjects practiced walking with and without the orthosis before we performed the gait
89 analysis. Each subject was asked to stand still for one second to allow all of the cameras to
90 record the markers to analyze the subject’s initial anatomical position. Each subject was
91 then measured walking at a self-selected, comfortable speed in each of three orthotic trials
92 (barefoot without an AFO, with a P-AFO, and with an A-AFO) during the same session.
93 The order of the three trials was randomized. Subjects were allowed to rest for 5 minutes
94 between trials. The walkway was carpeted to avoid any discomfort when the subjects
95 walked barefoot without an AFO. To reduce measurement errors during gait analysis, data
96 were collected from three successful trials. The data from these three trials were averaged
97 and the results were used for the statistical analysis.

98 **Data analysis**

99 A LabView software package^d was designed to analyze rear-foot motion. A joint
100 coordinate system examined the relative rotation matrices of the marker reference frames

101 on the calcaneus with respect to those on the shank. The neutral position was defined as the
102 standing position. The calculated rotation matrices in the neutral position were used to
103 correct the joint. Euler angles were used to define the three-dimensional relative joint
104 angular motion. From this neutral position, the distal segment was assumed to move
105 through three successive finite rotations to attain its new configuration. The first rotation
106 was dorsiflexion–plantarflexion about the z -axis of the proximal segment, followed by
107 inversion–eversion about a rotated floating x -axis. Finally, the third rotation was the
108 abduction–adduction rotation about the distal to proximal direction (y -axis) of the distal
109 segment. The temporal and spatial gait parameters were computed, including walking speed,
110 step length, cycle time, and angles of the rear-foot joint.

111 **Statistical Analysis**

112 We used SPSS version 12 software^e for the statistical analysis. Group differences in age,
113 body height, and body mass were compared using an independent t -test. Gender differences
114 between the groups were determined using a χ^2 test. The gait parameters were compared
115 using repeated measures analysis of variance (ANOVA) to determine significant differences
116 among the AFOs and groups. *Post hoc* Bonferroni tests were used to evaluate the
117 significance of pairwise comparisons between the AFOs. The level of significance used was
118 $P < 0.05$.

119 **Results**

120 Descriptive information regarding the 14 participants with hemiplegia is listed in table 1.
121 Comparisons of demographic data, including age, gender, body height, and body weight
122 between the stroke and normative subjects are listed in table 2. The hemiplegic stroke
123 subjects walked at a significantly slower, self-selected, comfortable walking speed, had
124 decreased step length, and longer cycle times than the control group. When comparing the
125 A-AFO, P-AFO, and barefoot conditions in the hemiplegic stroke subjects, there was no
126 significant difference in the self-selected, comfortable walking speeds, step lengths, and
127 cycle times (see table 3).

128 Rear-foot kinematic changes during gait in both the stroke and normal subjects when
129 barefoot are shown in table 4 and figure 3. At initial heel contact, the rear-foot movement
130 of the stroke patients showed increased inversion and adduction in comparison with the
131 healthy control subjects. During the stance phase, the stroke patients showed less
132 dorsiflexion and more inversion in the rear-foot angle. During the swing phase, the
133 rear-foot of the stroke patients showed less maximal plantarflexion and less dorsiflexion
134 than the healthy control group. Actually, they all showed the gait pattern as equinovarus
135 gait.

136 Comparisons of the rear-foot angular motions in hemiplegic stroke subjects in the
137 A-AFO, P-AFO, and without AFO conditions are shown in figures 3 and 4. In the sagittal
138 plane, as compared to walking with an A-AFO or without an AFO, the P-AFO significantly

139 decreased plantarflexion to neutral at initial heel contact and the swing phase and increased
140 dorsiflexion at the stance phase. In the coronal plane, the A-AFO significantly increased
141 maximal eversion to neutral (less inversion) at the stance phase and decreased the maximal
142 inversion angle at the swing phase when compared with not using an AFO. The P-AFO also
143 decreased the maximal inversion angle at the swing phase when compared with not using
144 an AFO. In the transverse plane, as compared to walking without an AFO, the A-AFO and
145 P-AFO conditions decreased the adduction angle significantly at initial heel contact. There
146 were no significant differences in maximal adduction and the maximal abduction angles
147 among the three AFO conditions during the stance and swing phases respectively.

148 **Discussion**

149 The incidence of equinovarus foot in stabilized vascular hemiplegia was reported to be
150 about 18%.¹⁷ The equinovarus foot shifts weight bearing from the heel to the lateral plantar
151 surface, which can cause loss of balance and reduce walking safety. This condition also has
152 a strong correlation to the presence of claw toes.^{18, 19} An AFO has often been prescribed to
153 facilitate ankle control for the equinus and/or varus foot. This study investigated the
154 kinematic change in rear-foot joint control during gait in hemiplegic stroke patients using
155 A-AFOs, P-AFOs, and no AFO assistance. As compared to using no AFO, the A-AFO
156 decreased rear-foot inversion at the stance and swing phases. The P-AFO increased
157 rear-foot dorsiflexion during the whole gait cycle in comparison with the A-AFO and

158 P-AFO. The P-AFO also decreased rear-foot inversion at the swing phase as compared to
159 using no AFO.

160 In comparison with the normal controls in our study, the stroke subjects showed
161 significantly decreased gait parameters including walking speed, step length, and cycle time.

162 After wearing either the A-AFOs or P-AFOs, we noted no significant differences in the
163 walking speed, step lengths, and cycle times after statistical analysis. Such results were not

164 compatible with the previously mentioned studies,⁴⁻⁶ but were similar to other studies.^{1, 20, 21}

165 The relatively small number of cases, variable improvement in patients' wearing different

166 types of AFO, (improvement in gait speed when wearing A-AFOs as opposed to decreases

167 in gait speed when wearing P-AFOs or vice versa), may explain the insignificant statistical

168 results. According to the study of Perry et al, a difference of 20 cm/s in walking speed was

169 defined as clinically significant.²² Even though some studies showed an improvement in

170 gait speed in stroke patients after wearing AFOs, most of the improvements were too small

171 to reach clinical significance.⁵

172 In healthy subjects, the rear-foot tended to plantarflex at initial heel contact, and then

173 dorsiflex during the stance phase and mid-swing phase in the sagittal plane. In the coronal

174 plane, the rear-foot inverted at initial heel contact and then everted until terminal stance

175 when it inverted. These findings are compatible with previous studies.^{12,15} W. Liu et al

176 evaluated rear-foot kinematic changes in healthy subjects and found that repeatable patterns

177 between subjects can be observed in dorsiflexion/plantarflexion and inversion/eversion,
178 suggesting that these characteristic changes are essential for efficient level walking. The
179 inconsistent kinematic changes in the abduction/adduction angle between the studies may
180 be explained by the angle's secondary importance to level walking. Each individual may
181 adopts his/her own strategy and his/her specific motion characteristics.²³

182 We noted that hemiplegic stroke subjects have altered rear-foot kinematics during gait,
183 such as rear-foot inversion and adduction at initial heel contact. It has been suggested that
184 foot eversion during the stance phase provides shock absorption on floor impact.²⁴
185 Increased rear-foot inversion at initial heel contact only offers shock absorption from the
186 toe and lateral border of the foot, but increases the stress on the contact area.²⁵ During the
187 stance phase, rear-foot control in the hemiplegic stroke patients became more plantarflexed
188 and still inverted. This plantarflexion and rear-foot inversion may interfere with adequate
189 pushing motion generation during propulsion.²⁶ During the swing phase of stroke subjects,
190 the rear-foot remained in the plantarflexion position and could not accomplish dorsiflexion
191 well. Inadequate dorsiflexion may interfere with foot clearance. Perry found that the
192 hemiplegic stroke patients had inadequate shock absorption at heel strike, poor control of
193 momentum during stance, and inadequate excursion of the paretic limb during swing.²⁷ Our
194 study suggests that these observations may be explained by the abnormal kinematic
195 changes in rear-foot control in our stroke patients.

196 After hemiplegic stroke subjects wore the two types of AFOs, their rear-foot control at
197 initial heel contact was in a more dorsiflexed position with P-AFOs as compared to the
198 A-AFOs and no AFO, and was less adducted with both the A-AFOs and P-AFOs when
199 compared to using no AFO. During the stance phase, the P-AFO increased the dorsiflexion
200 angle when compared with the A-AFO and no AFO, while the A-AFO corrected an inverted
201 rear-foot more effectively when compared with not using an AFO. At the swing phase, the
202 P-AFO kept the rear-foot in the dorsiflexion position in comparison with the A-AFO and no
203 AFO, and both the A-AFO and P-AFO decreased the inverted angle as compared to using
204 no AFO. The kinematic findings for the P-AFO in the sagittal plane were compatible with
205 Stefania Fatone et al's study, which showed that all patients tested with P-AFOs with
206 different AFO alignments and foot-plate lengths were able to decrease their plantar flexion
207 of the ankle at initial contact and mid-swing.¹ Our study also suggested that the A-AFOs
208 had a greater effect on inverted rear-foot control than the P-AFOs and going barefoot,
209 especially in the stance phase.

210 We speculated that the different effects of AFO type on the rear-foot kinematic change
211 may relate to the design differences. The P-AFO, with its sole extending the length from
212 heel to sulcus and posterior reinforcement to stiffen its plantar flexion resistance feature,
213 may prevent ankle plantarflexion effectively. Their medial and lateral trim lines posterior to
214 both malleoli allowed sufficient flexibility and helped dorsiflexion effectively but helped

215 less in controlling inverted ankle. The A-AFO, with its small sole band just under the
216 metatarsal and lack of posterior reinforcement, may have limited its ability to prevent
217 plantarflexion. However, its continuous coverage from the metatarsal and tarsal to shank
218 may fix the subtalar joint and prevent rear-foot inversion more effectively. Although the
219 rear-foot kinematics after AFO correction were still different from those of the normal
220 subjects, the A-AFOs and P-AFOs did play a role in correcting and normalizing the
221 rear-foot angle of hemiplegic subjects after statistical analysis. Such change may contribute
222 to the functional improvement noted in previously mentioned studies in gait stability,
223 balance control, energy cost, and patients' function. Other integrated strategies are still
224 needed to improve stroke patients' gait pattern.²⁸

225 There are some limitations in this study. First, a relatively small number of cases were
226 recruited for this study. Second, the healthy control group did not walk as slowly as the
227 stroke subjects, given that forcing such a slow speed on a healthy person would result in
228 unnatural gait patterns and thereby increase the variables. Third, we studied the rear-foot
229 kinematic change as representative of the ankle joint, since it can be easily marked and
230 compared well with the typical ankle gait analysis¹³. Fourth, we only analyzed the
231 posterior leaf-spring AFO, which provide little effects in controlling inverted ankle, in
232 representative of P-AFO in this study. Further study should evaluate the rear-foot, mid-foot,
233 and fore-foot motions under different AFO designs and conditions.

234 **Conclusions**

235 The results of our study suggested that for post-stroke hemiplegic gait, the P-AFO was
236 better than A-AFO in enhancing rear-foot dorsiflexion during the whole gait cycle. The
237 A-AFO was superior to the P-AFO in correcting excessive rear-foot inversion at the stance
238 phase. Both the A-AFOs and P-AFOs helped correct inverted foot at the swing phase. The
239 choice between A-AFO and P-AFO should not only be made by considering the patients'
240 preference and the practitioners' expertise, but should also be based on the patients' motor
241 control and resultant gait characteristics. We report our results here in anticipation that they
242 will be applied to AFO selection in hemiplegic stroke patients.

243 **Acknowledgement:**

244 This research was supported by the National Science Council, R. O. C. (grant no.:
245 NSC-95-2221-E-033-027)

246

247 **References**

- 248 1. Fatone S, Gard SA, Malas BS. Effect of ankle-foot orthosis alignment and foot-plate
249 length on the gait of adults with poststroke hemiplegia. *Arch Phys Med Rehabil*
250 2009;90(5):810-8.
- 251 2. Kim CM, Eng JJ. Magnitude and pattern of 3D kinematic and kinetic gait profiles in
252 persons with stroke: relationship to walking speed. *Gait Posture* 2004;20(2):140-6.
- 253 3. Lehmann JF, Condon SM, Price R, deLateur BJ. Gait abnormalities in hemiplegia:
254 their correction by ankle-foot orthoses. *Arch Phys Med Rehabil* 1987;68(11):763-71.
- 255 4. Abe H, Michimata A, Sugawara K, Sugaya N, Izumi S. Improving gait stability in
256 stroke hemiplegic patients with a plastic ankle-foot orthosis. *Tohoku J Exp Med*
257 2009;218(3):193-9.
- 258 5. de Wit DC, Buurke JH, Nijlant JM, Ijzerman MJ, Hermens HJ. The effect of an
259 ankle-foot orthosis on walking ability in chronic stroke patients: a randomized controlled
260 trial. *Clin Rehabil* 2004;18(5):550-7.
- 261 6. Tyson SF, Thornton HA. The effect of a hinged ankle foot orthosis on hemiplegic gait:
262 objective measures and users' opinions. *Clin Rehabil* 2001;15(1):53-8.
- 263 7. Wang RY, Lin PY, Lee CC, Yang YR. Gait and balance performance improvements
264 attributable to ankle-foot orthosis in subjects with hemiparesis. *Am J Phys Med Rehabil*
265 2007;86(7):556-62.

- 266 8. Corcoran PJ, Jebsen RH, Brengelmann GL, Simons BC. Effects of plastic and metal
267 leg braces on speed and energy cost of hemiparetic ambulation. *Arch Phys Med Rehabil*
268 1970;51(2):69-77.
- 269 9. Bleyenheuft C, Caty G, Lejeune T, Detrembleur C. Assessment of the Chignon
270 dynamic ankle-foot orthosis using instrumented gait analysis in hemiparetic adults. *Ann*
271 *Readapt Med Phys* 2008;51(3):154-60.
- 272 10. Park JH, Chun MH, Ahn JS, Yu JY, Kang SH. Comparison of gait analysis between
273 anterior and posterior ankle foot orthosis in hemiplegic patients. *Am J Phys Med Rehabil*
274 2009;88(8):630-4.
- 275 11. Wong AM, Tang FT, Wu SH, Chen CM. Clinical trial of a low-temperature plastic
276 anterior ankle foot orthosis. *Am J Phys Med Rehabil* 1992;71(1):41-3.
- 277 12. Chen CK, Hong WH, Chu NK, Lau YC, Lew HL, Tang SF. Effects of an anterior
278 ankle-foot orthosis on postural stability in stroke patients with hemiplegia. *Am J Phys Med*
279 *Rehabil* 2008;87(10):815-20.
- 280 13. Leardini A, Benedetti MG, Berti L, Bettinelli D, Nativo R, Giannini S. Rear-foot,
281 mid-foot and fore-foot motion during the stance phase of gait. *Gait Posture*
282 2007;25(3):453-62.
- 283 14. Ragnarsson KT. Lower extremity orthotics, shoes, and gait aids. In: JA Delisa, editor.
284 *Physical medicine & rehabilitation: principles and practice* 4th ed. Philadelphia: Lippincott,

285 Williams & Wilkins; 2005. p 1383-5.

286 15. Brunnstrom S. Motor testing procedures in hemiplegia: based on sequential recovery
287 stages. *Phys Ther* 1966;46(4):357-75.

288 16. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of
289 muscle spasticity. *Phys Ther* 1987;67(2):206-7.

290 17. Verdie C, Daviet JC, Borie MJ, Popielarz S, Munoz M, Salle JY et al. [Epidemiology
291 of pes varus and/or equinus one year after a first cerebral hemisphere stroke: apropos of a
292 cohort of 86 patients]. *Ann Readapt Med Phys* 2004;47(2):81-6.

293 18. Reiter F, Danni M, Lagalla G, Ceravolo G, Provinciali L. Low-dose botulinum toxin
294 with ankle taping for the treatment of spastic equinovarus foot after stroke. *Arch Phys Med
295 Rehabil* 1998;79(5):532-5.

296 19. Laurent G, Valentini F, Loiseau K, Hennebelle D, Robain G. Claw toes in hemiplegic
297 patients after stroke. *Ann Phys Rehabil Med* 2010;53(2):77-85.

298 20. Beckerman H, Becher J, Lankhorst GJ, Verbeek AL. Walking ability of stroke patients:
299 efficacy of tibial nerve blocking and a polypropylene ankle-foot orthosis. *Arch Phys Med
300 Rehabil* 1996;77(11):1144-51.

301 21. Cruz TH, Dhaher YY. Impact of ankle-foot-orthosis on frontal plane behaviors
302 post-stroke. *Gait Posture* 2009;30(3):312-6.

303 22. Perry J, Garrett M, Gronley JK, Mulroy SJ. Classification of walking handicap in the

304 stroke population. Stroke 1995;26(6):982-9.

305 23. Liu W, Siegler, S., Hillstrom, H. and Whitney, K. Three-dimensional,
306 six-degrees-of-freedom kinematics of the human hindfoot during the stance phase of level
307 walking. Human Movement Science 1997;16:283-98.

308 24. Perry J. Gait analysis: normal and pathological function. NJ: SLACK Incorporated,
309 Thorofare; 1992.

310 25. Turner DNCaMS. An Atlas of Lower Limb Orthotic Practice. London: Chapman &
311 Hall; 1997.

312 26. Levinger P, Gilleard W. Tibia and rearfoot motion and ground reaction forces in
313 subjects with patellofemoral pain syndrome during walking. Gait Posture 2007;25(1):2-8.

314 27. Perry J. The mechanics of walking in hemiplegia. Clin Orthop Relat Res
315 1969;63:23-31.

316 28. Dickstein R. Rehabilitation of gait speed after stroke: a critical review of intervention
317 approaches. Neurorehabil Neural Repair 2008;22(6):649-60.

318

319 **Supplier**

320 a. Orfit Industries n.v., Vosveld 9a, B-2110 Wijnegem, Belgium.

321 b. Sammons Preston, PO Box 93040 Chicago, IL 60673-3040 USA.

322 c. VICON, Oxford Metrics Limited, 14 Minns Estate, West Way, Oxford, OX2 OJB UK.

323 d. National Instruments 11500 N. Mopac Expwy. Austin, TX 78759-3504. USA.

324 e. SPSS Inc, 233 S Wacker Dr, 11th Fl, Chicago, IL 60606 USA.

325

326 **Figure Legends**

327 Figure 1. A piece of thermoplastic was cut in the shape of a bottle cap opener

328 Figure 2. The arrangement of markers on the shank and calcaneus in anterior AFO (A, B)

329 and posterior AFO (C, D) conditions

330 Figure 3. Angular motion of rear-foot in both groups: plantarflexion (+); dorsiflexion (-);

331 inversion (+); eversion (-); adduction (+); abduction (-); Asterisks (*) indicate points in the

332 gait cycle where the difference in angles with and without AFOs was significantly different.

333 Vertical lines indicate mean toe-off for each cycle with and without AFOs. The solid line

334 shows toe-off for the A-AFO trial, the dash line for the P-AFO trial, and the dot line for

335 toe-off without an AFO.

336 Figure 4. Angular comparisons of rear-foot with and without AFOs. *: $P < 0.05$;

337 plantarflexion (+), dorsiflexion (-); inversion (+), eversion (-); adduction (+), abduction (-).

Table 1: Information about stroke subjects with hemiplegia

Subject Number	Sex	Age(y)	Years and months since stroke	Involved Side R/L	Brunnstrom stage of involved lower limb	Ankle MAS	Use of assistive device	Prior AFO use
1	M	47	5y6m	L	V	3	N	Y(A-AFO)
2	M	51	3y8m	L	IV	3	N	Y(A-AFO)
3	M	47	3y9m	R	V	1+	N	N
4	M	67	2y5m	L	IV	1+	N	N
5	M	60	7m	R	III-IV	3	N	Y(A-AFO)
6	M	53	5y4m	R	V	2	N	N
7	M	53	8m	L	III	2	N	N
8	M	51	3y4m	R	III	3	N	Y(A-AFO)
9	M	43	10m	L	V	2	N	Y(A-AFO)
10	W	70	5m	R	V	1+	N	N
11	W	49	2m	R	IV	2	N	Y(A-AFO)
12	W	56	2y2m	R	IV	2	N	Y(A-AFO)
13	W	72	1y	R	V	2	N	N
14	W	71	4y4m	L	IV	1+	N	Y(A-AFO)

MAS:Modified Ashworth Scale. N: no, Y: yes.

Table 2. Comparisons of demographic data between stroke and normative subjects

Demographic data	Stroke subjects (n=14)	Normal subjects (n=11)	<i>P</i> value
Age (years)	56.4 ± 9.8	55.6 ± 8.2	0.842
Gender (Men/Women)	9/5	5/6	0.435
Body height (cm)	161.0 ± 9.5	158.3 ± 5.6	0.415
Body mass (kg)	64.0 ± 9.7	60.9 ± 9.9	0.439

Table 3. Gait parameters of AFO conditions in stroke subjects and normal subjects

Plane	Stroke patients			Normal subjects
	A-AFO	P-AFO	Barefoot	Barefoot
Speed (%BH/sec)	32.8±11.1	31.6±10.9	31.9±11.6	66.5±3.9
Step length (%BH)	9.6±6.2	9.2±5.9	9.8±6.6	29.4±4.1
Cycle time (sec)	4.0±1.4	4.2±1.4	3.9±1.5	2.2±0.3

Table 4. Rear-foot kinematics during gait for the involved limb of stroke subjects and control subjects walking barefoot with their self-selected, comfortable walking speed.

Gait phase	Initial heel contact	Stance phase	Swing phase
Sagittal plane	Plantarflexion	Maximal Dorsiflexion	Maximal Plantarflexion
Angle (degree)			
Control	6.3±4.7	-8.6±2.9	8.4±3.6
Stroke	8.5±5.7	-2.4±6.4	5.4±4.0
<i>P</i> -value	0.307	0.018*	0.048*
Coronal plane	Inversion	Maximal Eversion	Maximal Inversion
Angle (degree)			
Control	-1.4±2.8	-4.6±3.0	7.7±2.6
Stroke	8.2±4.5	4.4±5.0	10.5±4.7
<i>P</i> -value	<0.001**	<0.001**	0.177
Transverse plane	Adduction	Maximal Adduction	Maximal Abduction
Angle (degree)			
Control	1.2±3.6	11.3±4.5	7.7±2.6
Stroke	8.9±4.3	11.5±5.5	3.7±5.4
<i>P</i> -value	<0.001**	0.850	0.118

*: $P < 0.05$; **: $P < 0.01$; plantarflexion (+), dorsiflexion (-); inversion (+), eversion (-); adduction (+), abduction (-).

Figure 1



Figure 2




Figure 3





Figure 4



CHECKLIST

Incomplete submissions will not be put into peer review until requirements are met.

A more complete description of each item that must be checked is provided under the appropriate heading in the Information for Authors.

General

- ✓ The cover letter with essential information, including statement of information on corresponding author and statement signed by corresponding author that written permission has been obtained from all persons named in the Acknowledgments.
- ✓ All elements of the manuscript are printed in English and double-spaced with 1-inch margins at top, bottom, and sides. Right margins are unjustified.
- ✓ All pages are numbered in the following order: title page, structured or standard abstract, body of the text, acknowledgments, references, legends, and tables.
- ✓ The text is consecutively line numbered.
- If this is a randomized controlled trial, provide the CONSORT flow diagram (<http://www.consort-statement.org/Downloads/flowchart.doc>).
- ✓ The Disclosure Statements & Copyright Assignment form signed by the guarantor at original submission. If a resubmission, then **all** authors must submit the Disclosure Statements & Copyright Assignment form. In either case, the author uploading the submission must insert the selected financial disclosure into the title page of the manuscript.
- ✓ Human experimentation has been approved by the local institutional review board or conforms to Helsinki Declaration as stated in the section Manuscript Preparation, Methods.
 - Guidelines for the care use of nonhuman animals or other species approved by the institution have been followed as indicated in the Methods. The species is named in the title, abstract, and Methods section.
 - Signed, written permission from both the copyright holder and the original author for the use of tables, figures, or quotations previously published and their complete references is on file with the author and can be submitted to the editorial office on request.
 - Signed, written permission for the use of quotations of personal communications and unpublished data has been obtained from the person(s) being quoted and is enclosed.
- ✓ It is recommended that a professional editor or a colleague fluent in English edit before submission of manuscripts by authors whose first language is not English.
- ✓ When resubmitting a manuscript for further consideration, provide an itemized accounting of how the manuscript was changed in response to the original set of evaluations.

Similar Publication

- Attached is a reprint of each article and/or abstract the author and/or coauthors have previously published or is “in press,” and each manuscript the author and/or coauthors have submitted for possible publication or have in manuscript form dealing with the same patients, animals, laboratory experiment, or data, in part or in full, as those reported in the submitted manuscript. Further explanation of the circumstances is included. Similarities and differences are explained in the cover letter.

Title Page

These elements are in the following sequence, and are typed double spaced.

- ✓ Word counts for the main text (from opening paragraph through conclusions) and Abstract.
- ✓ Running head of no more than 40 character spaces.
- ✓ Title.
- ✓ Author(s) full name(s) and highest academic degree(s) are included.
- ✓ The name(s) of the institution(s), section(s), division(s), and department(s) where the study was performed are provided and the institutional affiliation(s) of the author(s) at the time of the study is indicated.
- Acknowledgment of any presentation of this material, to whom, when, and where.
- ✓ Acknowledgment of financial support.
- Requisite financial disclosure as selected from the Disclosure Statements & Copyright Assignment form and an explanation of any conflicts of interest.
- ✓ Name, address, business and home telephone numbers, fax number, and e-mail address of corresponding author and author from whom reprints can be obtained.
- If reprints are not available, this is stated on the title page.
- Clinical trial registration number.

Abstract

- ✓ A structured abstract (eg, Articles, Review Articles) with Key Words is on page 2 and is headed by the title.
- A standard abstract of 200 words or fewer (eg, Clinical Notes) with Key Words is on page 2 and is headed by the title.

References

- ✓ All references have been checked for accuracy and completeness.
- ✓ Are numbered consecutively in the order they are cited in the text; all listed references have been cited in the text.
- ✓ The format prescribed by the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" has been followed. Examples provided under Manuscript Preparation have been uploaded.
- For any reference cited as "in press," a copy of the article is included.
- Personal communications and unpublished observations are not used as numbered references but are mentioned in the text with the written approval of the person being quoted. Author must produce a copy of the approval if so required by the editors.

Suppliers

- ✓ Provide a list (after the Reference section) including all manufacturers and other nondrug products used directly in the study.
- ✓ Provide names and complete mailing addresses for each Supplier.
- ✓ Equipment and/or materials are identified in text, tables, and legends by superscript lower case letters.
- ✓ Suppliers are listed consecutively in the order they are cited in the text.

Figures

- ✓ Each is numbered with an Arabic numeral and cited in numeric sequence in the text.
- Photographs of recognizable persons should be accompanied by a signed release from the patient or legal guardian authorizing publication. Masking eyes to hide identity is not sufficient.

Figure Legends

- ✓ Are provided for each figure.
- ✓ Are numbered and presented together in numeric order following Reference page(s).

Tables

- ✓ Each table is headed by a title and numbered in Arabic numerals on a separate page.
- ✓ Tables are cited in numeric sequence in the text.

Credits & Permissions

- In addition to the notice of informed consent and releases to publish photographs of recognizable persons, submit with the manuscript written permission to use nonoriginal material (quotations exceeding 100 words, any table or illustration) from both author and publisher of the original. No article will be accepted as a submission to *Archives* without all required permissions. Credit the source in a text or table footnote or in a legend.

Reviewers

✓ Submit the names of 3 potential reviewers and their addresses, telephone numbers, and email address (if known). Do not submit names of people affiliated with your institution.

I have reviewed this Checklist and have complied with its requirements.

____ Chih-Chi Chen _____ ____ 2010726 _____

Type in name above

Type in date above


DISCLOSURE STATEMENTS & COPYRIGHT ASSIGNMENT

Disclosure During Revision of Evaluation in Progress: Each coauthor must complete and sign a separate copy of this document. Email PDF to archivesmail@archives.acrn.org or the completed forms can be faxed to 312-238-7821 to the Editorial Office.


The manuscript code number is: ARCHIVES-PMR-D-10-00494.

Manuscript Title: Kinematic features of rear-foot motion using anterior and posterior AFOs in stroke patients with hemiplegic gait

Authorship Responsibility: I have read the submitted manuscript that includes my name as an author and vouch for its accuracy. I certify that I have participated sufficiently in the conception and design of this work and the analysis of the data (where applicable), as well as the writing of the manuscript, to take public responsibility for its content. I believe the manuscript represents honest and valid work. To the best of my knowledge, it contains no misrepresentations. I have reviewed the final version of the submitted manuscript and approve it for publication. If requested, I shall produce the data on which the manuscript is based for examination by *Archives* or its assignees.

Signature: 

Prior or Duplicate Publication: I warrant that the manuscript is original and its essential substance, tables, or figures have not been previously published in part or in whole. The manuscript or one with substantially similar content under my authorship or the data within it has not been accepted for publication elsewhere and it is not presently under review by any other publisher. The manuscript will not be submitted for publication elsewhere until a decision has been made on its acceptability for publication in *Archives*. This restriction does not apply to brief abstracts or press reports published in connection with scientific meetings.

Signature: 

Financial Disclosure: Choose one of the following statements. Insert the selected Financial Disclosure into the title page of the manuscript submission.

- I certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on me or on any organization with which I am associated AND, if applicable, I certify that all financial and material support for this research (eg, NIH or NHS grants) and work are clearly identified in the title page of the manuscript.
- I certify that I have affiliations with or financial involvement (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants and patents received or pending, royalties) with an organization or entity with a financial interest in, or financial conflict with, the subject matter or materials discussed in the manuscript AND all such affiliations and involvements are disclosed on the title page of the manuscript.

Device Status Statement: Choose one of the following 10 statements:

- The manuscript submitted does not contain information about medical device(s).
- The device(s) is/are FDA approved for the indicated usage in the United States.
- The legal/regulatory status of the device(s) that is/are the subject of this manuscript is/are not applicable in the country where the author(s) resides.
- The device(s) that is/are the subject of this manuscript has/have been cleared through the Premarket Notification (510(k)) process/approved through a Premarket Approval application for the indications studied.
- The device(s) that is/are the subject of this manuscript has/have been cleared through the Premarket Notification (510(k)) process/approved through a Premarket Approval application for [state the specific indication on a separate page and attach], but not for the indications that were reported.
- The device(s) that is/are the subject of this manuscript is/are being evaluated as part of an

ongoing FDA-approved investigational protocol (DE) for [state the intended use on a separate page and attach].

- The device(s) that is/are the subject of this manuscript is/are exempt from FDA regulations because [state reason on a separate page and attach].
- The device(s) that is/are the subject of this manuscript is/are not FDA-approved and is/are not commercially available in the United States.
- The device(s) that is/are the subject of this manuscript is/are not intended for human use.
- The legal/regulatory status of the device(s) that is/are subject of this manuscript is/are not known by the author(s).

Signature: Simon Tang

Institutional Review Board/Animal Care Committee Approval: I certify that my institution or the appropriate regional institution has approved the protocol for any investigation involving humans or animals and that all investigation was conducted in conformity with the protocol and the ethical and humane principles of research. *Archives* reserves the right to contact your institution.

Signature: Simon Tang

Copyright Transfer: In consideration of the *Archives of Physical Medicine and Rehabilitation (Archives)* reviewing and editing this submission, the author undersigned hereby transfers, assigns, or otherwise conveys all rights, title, and interests therein, including any and all copyrights in all forms and media, now or hereafter known, to *Archives* in the event that such work is published by *Archives*. Should *Archives* not publish the aforesaid submission, it agrees to release its rights therein. (Note: material prepared by employees of the federal government in the course of their official duties may not be copyrightable.)

Each author must complete and sign a copy of this statement, to be either scanned and e-mailed, or faxed to (312) 238-7821.

Signature Simon Tang

Date July 20, 2010

Print name SHIMON FT TANG

Note to US Government Employees

A work prepared by a US federal government employee as part of his/her official duties is called a "US Government work," and is in the public domain in the United States; in such case, Copyright Transfer above applies only outside the United States. Please attach a copy of any applicable policy of the author's agency.

If the Work was prepared jointly, and any coauthor is not a U.S. government employee, it is not a US Government work. If the Work was not prepared as part of the employee's duties, it is not a US Government work.

- If this article is a US Government work, check this box.

This document may be provided confidentially to the American Congress of Rehabilitation Medicine specifically to fulfill the provisions of accreditation of the Accreditation Council for Continuing Medical Education.